X0508 4 2023-12-15 0001042074 CymaBay Therapeutics, Inc. CBAY 0001705745 Menold Daniel C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560 0 1 0 0 Vice President, Finance 1 Common Stock 2023-12-15 4 M 0 10000 4.05 A 10000 D Common Stock 2023-12-15 4 S 0 10000 21.9847 D 0 D Common Stock 2023-12-15 4 M 0 11497 8.43 A 11497 D Common Stock 2023-12-15 4 S 0 11497 21.9883 D 0 D Employee Stock Option (right to buy) 4.05 2023-12-15 4 M 0 10000 0 D 2030-05-14 Common Stock 10000 145109 D Employee Stock Option (right to buy) 8.43 2023-12-15 4 M 0 11497 0 D 2029-01-28 Common Stock 11497 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.70 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares subject to the option vest in 48 equal monthly installments commencing on January 31, 2020. The shares subject to the option vest as to 1/4 of the underlying shares on January 1, 2020, and vest as to 1/48 of the underlying shares monthly thereafter. /s/ Paul Quinlan, as attorney-in-fact for Daniel Menold 2023-12-15